Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation – a meta-analysis of more than 17000 patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation – a meta-analysis of more than 17000 patients ; volume:9 ; number:1 ; day:28 ; month:2 ; year:2019 ; pages:1-9 ; date:12.2019
Scientific reports ; 9, Heft 1 (28.2.2019), 1-9, 12.2019
- Urheber
-
Mincu, Raluca Ileana
Mahabadi, Amir Abbas
Totzeck, Matthias
Rassaf, Tienush
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-019-39925-5
- URN
-
urn:nbn:de:101:1-2019032019203149556139
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 11:04 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mincu, Raluca Ileana
- Mahabadi, Amir Abbas
- Totzeck, Matthias
- Rassaf, Tienush
- SpringerLink (Online service)
Ähnliche Objekte (12)
Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
New Anticoagulants for Atrial Fibrillation
New Anticoagulants for Atrial Fibrillation
Clinical factors associated with safety and efficacy in patients receiving direct oral anticoagulants for non-valvular atrial fibrillation
Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation
Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis
Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims
Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
New Anticoagulants for Atrial Fibrillation
New Anticoagulants for Atrial Fibrillation
Clinical factors associated with safety and efficacy in patients receiving direct oral anticoagulants for non-valvular atrial fibrillation
Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation
Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis
Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims
Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
New Anticoagulants for Atrial Fibrillation
New Anticoagulants for Atrial Fibrillation
Clinical factors associated with safety and efficacy in patients receiving direct oral anticoagulants for non-valvular atrial fibrillation
Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation
Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis
Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation